Articles Published in 2013

bioMérieux acquires BioFire Diagnostics

Wednesday, September 4, 2013 03:51 PM

bioMérieux, an in vitro diagnostics company, has acquired BioFire Diagnostics, a privately-held U.S.-based company specialized in molecular biology. BioFire invented, manufactures and commercializes its multiplex PCR FilmArray system, a simple and rapid molecular biology solution dedicated to the diagnosis of infectious diseases.

More... »

iPierian to launch True North Therapeutics

Wednesday, September 4, 2013 03:48 PM

iPierian, a biotechnology company developing novel therapies for neurodegenerative disease, has secured financing of $30 million  to continue to advance its drug development in neurodegenerative disease and  to launch a spin-out company, True North Therapeutics.

More... »

Elcelyx Therapeutics spins out NaZura BioHealth

Wednesday, September 4, 2013 03:47 PM

Elcelyx Therapeutics has established NaZura BioHealth, a separate company focusing on development of Gut Sensory Modulators (GSM) including lead product Lovidia, a dietary supplement for weight management. Elcelyx retains pharmaceutical product candidate NewMet, the company’s proprietary delayed-release formulation of metformin for the treatment of patients with type 2 diabetes. Elcelyx has funded NaZura with a credit line of $5 million, which will be used for clinical development of Lovidia and pre-commercial activities.

More... »

NICE responds to article in The Times

Wednesday, September 4, 2013 03:45 PM

The National Institute for Health and Care Excellence (NICE) has called on pharmaceutical companies to question the development costs of new medicines.

More... »

Covance, Indiana CTSI collaborate

Wednesday, September 4, 2013 12:28 PM

CRO Covance and the Indiana Clinical and Translational Sciences Institute (CTSI), part of the Indiana University (IU) School of Medicine, will collaborate to conduct early clinical trials for new medicines. 

More... »

MRC Technology, Parkinson’s U.K. launch “call for targets”

Wednesday, September 4, 2013 12:27 PM

MRC Technology, a technology transfer organization, and Parkinson’s U.K., a support and research charity, have announced a joint “call for targets.” The call aims to identify and fund either one or two projects focused on potential small molecule or antibody targets to slow, stop or reverse the progression of Parkinson’s. The call to academic researchers seeks to fund target validation and proof-of-concept studies prior to initiating a full-scale drug discovery project.

More... »

Brisk pace of drug outsourcing deals continues in first half of 2013

Wednesday, September 4, 2013 12:26 PM

Crosstree Capital Partners, an investment banking company specializing in advising middle market companies in the drug and device outsourcing industry, has released its second quarter 2013 Drug and Device Outsourcing Industry Monitor.

More... »

VelaLabs, Evercyte collaborate for biosimilar characterization

Wednesday, September 4, 2013 12:25 PM

VelaLabs, a provider of analytical services to the global biopharmaceutical industry, and Evercyte, a producer of standardized, relevant cell systems, are cooperating to commercialize immortalized target cells for the characterization of biosimilars in a GMP environment.

More... »

Clinverse, OmniComm Systems partner

Wednesday, September 4, 2013 12:23 PM

Clinverse, a global technology and eclinical commerce network for clinical trials, has formed a strategic partnership with OmniComm Systems, a provider of EDC solutions.

More... »

SLAS expands global operations with Brussels office

Wednesday, September 4, 2013 12:21 PM

The Society for Laboratory Automation and Screening (SLAS), an international community of more than 15,000 individual scientists, engineers, researchers and technologists from academic, government and commercial laboratories, has opened a European office in Brussels, Belgium. The SLAS Europe office becomes the Society’s third on three different continents, joining operations in Shanghai, China, and SLAS global headquarters in Chicago.

More... »